Path_MLH1 and path_MSH2 carriers showed similar high risk for CRC, endometrial and ovarian cancer, while path_MSH2 carriers had higher risk for other cancers such as upper gastrointestinal, urinary tract, prostate and brain. Here, MSH2 is linked to cancer.